Ellen Lubman

Ms. Ellen Lubman brings more than 20 years of biopharmaceutical business and financial industry experience to Werewolf Therapeutics, including global partnering, asset sourcing and acquisition, financial structuring and leading early-stage company operations, fundraising and board governance. She recently served as the Chief Business Officer at Impel NeuroPharma, Inc.

Prior to Impel, she was the Vice President of External Science & Innovation at Allergan, where, through two mergers from Forest Labs and Actavis, she was responsible for strategic expansion of the company’s diverse pipeline of therapeutics in a variety of disease areas. Ms. Lubman has held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank, and Abbott Labs. Ms. Lubman frequently advises emerging companies on business development strategy and fundraising. She serves on the Board of Directors of GeneCentric Therapeutics and IntrepidaBio, as well as the Advisory Board of TMRW.org. Ms. Lubman also currently serves on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell and Board of Directors of Gilda’s Club of NYC.

Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College.